Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.
about
Immunotherapy of systemic sclerosisTreatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectivesBiologics in dermatology: an integrated reviewAnalysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionationLow-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.Fatal antiphospholipid syndrome following endoscopic transnasal-transsphenoidal surgery for a pituitary tumor: A case report.Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.New insights into the prevention of staphylococcal infections and toxic shock syndrome.Primary immune deficiency in the intensive care unit: It is never too late to diagnose and treat.Plasma-derived medicines: access and usage issuesReduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies.Agents to reduce cytokine storm.Special considerations with the use of intravenous immunoglobulin in older persons.Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease.Immunoglobulins in adult sepsis and septic shock.Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness.Vasculitides and the Complement System: a Comprehensive Review.Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD.Challenges to develop novel anti-inflammatory and analgesic drugs.In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparationsSerum levels of immunoglobulins and severity of community-acquired pneumonia.Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis.Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin.High-resolution physicochemical characterization of different intravenous immunoglobulin products.Safety of intravenous immunoglobulin and plasma exchange in critically ill patients.Dose-dependent inhibition of demyelination and microglia activation by IVIG.Novel approaches in the treatment of myositis and myopathies.Use of intravenous immunoglobulin in an Asian paediatric population over a 10-year period.Bilateral uveitis following intravenous immunoglobulin administration.Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.Multispecificity of a recombinant anti-ras monoclonal antibody.Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets.
P2860
Q24634395-ABAA16DE-7F4D-4FAA-BA9C-11D6E91AC6FFQ26822442-B1010C41-989B-4EAB-B386-DA234BB46C7EQ27004638-6A50796A-2338-4208-8F8E-DB3B17BB5F14Q28728886-1428CD1D-12B0-4DC4-ACFF-B1C58192C04BQ33393434-886CDA14-BD24-43BF-B586-5644BA05A073Q33420853-F73482AA-6D85-4348-9314-D269710AF54BQ33438290-F4A774CA-54A7-4FBA-92AF-BDE514C97741Q33726086-ED7B7CC6-75C0-4C2D-8AD2-2DBB70318DE4Q35008802-D8D2E771-6BBA-444B-80D9-42B35FEDC02CQ35307125-259B2F8B-FEFD-49B4-ABF9-248BBAA75C67Q36159943-0CF1E95F-43AE-423C-A67C-4645309D4499Q37318222-4679538A-5F9C-4E72-8203-41EEC46DFD7AQ37340312-3402ABD9-4981-4DD5-BB37-90204F2C2CE0Q37577684-65D81606-3FDC-49D2-A818-44A220D638D7Q37931231-EEC77FC1-87C5-4739-AA22-0118C40CB807Q38027890-F8CE8721-F492-4AF2-B6FE-6A2CAEB1C65BQ38034107-6652CA9F-358E-4896-A775-2329D7551DE8Q38133405-487C0593-9ABC-4286-89B9-5E051445DB26Q38252398-6DC730B9-3CCC-4B9A-8D57-4CA8B4FFFD87Q38259908-0B0C29DA-63CB-4B8B-A644-EFDBC21FE3E4Q38310244-3D2010B4-57C2-421B-ABDC-22233AE378EAQ38615353-D0173B74-1A5C-49FB-86FB-6EF7CE704EB8Q38675216-E0DAFA55-97CB-4CFE-8DD3-4F0E5ADEC18FQ38739354-1D91D676-9BDB-470C-B123-6853FD958135Q38941483-7925A949-09A4-4ABD-A956-9ACAC8E464FCQ39273058-F00BDCB4-B36F-4CEC-ACE2-C104C7C130E5Q40417136-7CA6F219-3334-4E40-9A36-3BD99FB993FAQ40801411-BFDDD5E6-84E7-4529-B170-9999EBAC6C6BQ41038467-BF9ED2A2-A286-4A36-B7F0-E904447DEA61Q41185651-D3B6D736-00D0-48EF-9FB4-0215B2519ADBQ41442958-707D37C9-7A46-43EC-B767-1D11BA7A86E1Q41819438-1843AE96-BE5B-4D9F-B5CA-8E0EEFD5CBF2Q41977818-F965171F-8534-4668-A0EC-27551B4214ECQ44581890-3E623CB0-B1D0-485C-B756-F72F9477CE1CQ47108804-260B0711-267C-457A-8729-6F44216C9436Q47190029-075DF806-D1B8-4425-A447-61F68C127331Q47426223-D6554C22-7056-45B0-8F53-0CAF34CB8720Q49807763-53783548-1EE5-4DF3-B692-640DB9D9F2C7
P2860
Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical applications of intra ...... unodeficiencies and neurology.
@en
Clinical applications of intravenous immunoglobulins
@nl
type
label
Clinical applications of intra ...... unodeficiencies and neurology.
@en
Clinical applications of intravenous immunoglobulins
@nl
prefLabel
Clinical applications of intra ...... unodeficiencies and neurology.
@en
Clinical applications of intravenous immunoglobulins
@nl
P2093
P2860
P1476
Clinical applications of intra ...... munodeficiencies and neurology
@en
P2093
P2860
P356
10.1111/J.1365-2249.2009.04024.X
P478
158 Suppl 1
P577
2009-12-01T00:00:00Z